<DOC>
	<DOC>NCT00623636</DOC>
	<brief_summary>This is a randomized, double blind, placebo controlled, parallel group study of MAP0004 in adult migraineurs. Subjects will self administer study drug in the outpatient setting.</brief_summary>
	<brief_title>Phase 3 Study of MAP0004 in Adult Migraineurs</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Major Male or female between 18 and 65 years of age. History of episodic, acute migraine (with or without aura) with onset prior to 50 Major Known allergy or sensitivity or contraindication to study drugs or their formulations History of chronic pulmonary disease, coronary artery disease (CAD), liver disease, kidney disease, seizures, stroke, or major psychiatric condition. Any condition that, in the opinion of the Investigator, would make the subject unsuitable for study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Migraine</keyword>
</DOC>